The Spanish COPPADIS study started eleven years ago, in 2013, and has quickly become one of Europe’s largest studies of Parkinson’s.
It began as a draft created during a large Parkinson’s conference by a group of neurologists, members of the Spanish Movement Disorders Group (GETM) and the Spanish Society of Neurology (SEN), who wanted to investigate subjects including the evolution of Parkinson’s, quality of life of people with the condition, the burden on caregivers, and Parkinson’s biomarkers and causes.
The name COPPADIS stands for Cohort of Patients with Parkinson’s Disease in Spain, and today the study covers almost 700 people with Parkinson’s, as well as over 250 caregivers and 200 controls.
What started as a conversation has turned into something of real magnitude: the study has produced over 100 abstracts and papers, with one particularly interesting study in the Journal of Clinical Medicine explore sex differences in motor and non-motor Parkinson’s symptoms.
We talk to the study’s co-ordinator, Diego Santos García, and one of the study’s members, Paqui Ruiz, about what the study has achieved for Parkinson’s in Spain.

Diego Santos García, co-ordinator of COPPADIS
What’s your background?
I’m a Spanish neurologist, and the Coordinator of the Movement Disorders Unit from the Department of Neurology in CHUAC (Complejo Hospitalario Universitario de A Coruña in Galicia) and also I work in Hospital San Rafael, A Coruña.
I am Head of Research Group on Parkinson’s disease and Movement Disorders at the Biomedical Research Institute of A Coruña (INIBIC), President of the DEGEN Foundation, and Member of the Advisory Committee of the Spanish Parkinson’s Federation.
As well as COPPADIS, I’m coordinator of different projects including SAFINONMOTOR, OPEN-PD, VOPARK, and INLEVO-LIFE PD.
Actions aimed to patients have always been a priority for me, such as CONOCE EL PARKINSON, among others initiatives.
How and why was COPPADIS created?
The project was born with the intention to evaluate very comprehensively a population of patients with Parkinson’s in Spain for studying in detail the natural progression of the disease. It is one of the most complete international cohorts, with almost 700 patients included.
What is your role in this group?
I have had the pleasure of being able to coordinate and lead the project. It has helped me learn the great importance of being able to carry out networking or group work, joining efforts. More than 100 researchers from 35 centres in Spain have participated and we have carried out international collaborations.
What are the key achievements that you would like to highlight?
More than 70 abstracts have been presented at congresses and more than 40 articles have been published, in addition to having received several awards.
We have observed very interesting findings on motor aspects of the disease but also on non-motor symptoms, quality of life and autonomy for activities of daily living.
For example, we have observed that there are sex differences in Parkinson’s, such as fatigue or depression are more frequent in women. We also published a paper finding that non-motor symptoms are very prevalent and impact on quality of life of patients, and that motor complications are very frequent even in the early stages of the disease and are associated with a greater non-motor symptoms burden.
We found that depression affects 50% of patients throughout the course of the condition, and is related to impulse control behaviours, which we presented at the MDS Congress in 2018.
We’ve also learned not only that the patient’s condition impacts on the caregiver, but also vice versa: the caregiver’s overload impacts over the patient.
You can find lots more information about the findings of our research here.
We currently have three articles under review, one of them very interesting about the importance of educational level as a protective factor in the development of cognitive impairment in patients with Parkinson’s.
What is the COPPADIS group currently working on? What can we expect in the future?
Recruitment of participants ended in 2023, but we are waiting for the resolution of a public convocation for a research project from the Carlos III Institute. We have already carried out part of the COPPADIS project thanks to a grant from this institution. If we obtain it, we will perform DNA and microRNA genetic analyses of patient samples from the COPPADIS cohort.
One of the objectives is to try to obtain a panel of microRNAs that could predict the outcome of the disease. On the other hand, the project contemplated a five-year follow-up but we are considering making a new cut assessment at 10 years (in 2026 and 2027).
I’d like to thanks the Degen Foundation and other institutions helping as to develop the Project and specially thanks to the patients, caregivers and other participants.

Paqui Ruiz, a person with Parkinson’s and member of the COPPADIS study
Please tell us about yourself.
Most of the people close to me know me as Paqui Ruiz. I am 59 years old and live on the island of Tenerife. I was diagnosed with Parkinson’s in July 2012. I am president of the association Con P de Parkinson for women with Parkinson’s disease. I am also an ambassador for the Degén Foundation and the Davis Phinney Foundation.
How did you hear about the COPPADIS study? And how and when did you get involved?
I found out through my neurologist at the University Hospital of the Canary Islands in 2015, who invited my husband and me to participate in the study.
Have you had previous experience in participating in similar studies?
Subsequently, I have participated in other studies, but not as large as COPPADIS.
Why did you participate in this study? What was your involvement?
I agreed to take part in the study because, knowing that I have such a complex and incurable disease, my contribution and that of other participants could help researchers to learn more about this disease. The study did not only take into account the physical state of the person, but also the cognitive state of the person.
Once a year for five years I had appointments of more than two hours with my neurologist. I had to go without taking any medication and I did all the tests and repeated them again with the medication. My husband also had to participate by answering questions.
What were the study’s outcomes? Do they make sense to you as a person diagnosed with Parkinson’s?
The results were very positive, both as a patient with Parkinson’s disease and as a woman with Parkinson’s disease, because the study confirmed that Parkinson’s disease affects men and women differently.
What were the benefits of participating in this study to you as a person with Parkinson’s?
Because the more you know about Parkinson’s the sooner you can find a way to reverse or control the disease.
Find out more about the COPPADIS study and learn more about Parkinson’s research





















